Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs PTX 100 (Primary)
Indications Colorectal cancer; Cutaneous T-cell lymphoma; Gastric cancer; Multiple myeloma; Pancreatic cancer; Peripheral T-cell lymphoma; Solid tumours
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Prescient Therapeutics

12 Dec 2023 Preliminary Results of safety from this phase 1 dose escalation study, presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Sep 2021 Planned End Date changed from 30 Apr 2021 to 30 Apr 2023.
15 Sep 2021 Planned primary completion date changed from 30 Apr 2021 to 30 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com